Beta Bionics Projects $131M-$136M Revenue for 2026
BBNX sits 37% above its 52-week low of $8.8.
Summary
Beta Bionics has issued its revenue guidance for fiscal year 2026, projecting sales to be in the range of $131 million to $136 million. This new forward-looking financial information is significant for investors, providing a fresh basis for updating valuation models and assessing the company's near-term growth prospects. While the company's last 10-K reported strong 2025 revenue, this guidance offers the first official outlook for the current year. Traders will closely monitor this range against market expectations, as meeting or exceeding these projections will be a key catalyst for the stock.
At the time of this announcement, BBNX was trading at $12.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $544.6M. The 52-week trading range was $8.80 to $32.71. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.